| | Recommended treatment | HPV positive | HPV negative | | Men N = 8,860 | Women N = 1,350 | value | Men N = 3,020 | Women N = 953 | value |
| | All stages, N (%) | | No | 1,640 (18.5) | 305 (22.6) | 0.002 | 538 (17.8) | 202 (21.2) | 0.06 | | Yes | 7,198 (81.2) | 1,042 (77.2) | 2,474 (81.9) | 748 (78.5) | | Missing | 22 (0.3) | 3 (0.2) | 8 (0.3) | 3 (0.3) |
| | Stage I, N (%) | N = 5,098 | N = 878 | 0.02 | N = 214 | N = 121 | 0.18 | | No | 1,071 (21.0) | 220 (25.1) | 17 (7.9) | 5 (4.1) | | Yes | 4,013 (78.7) | 655 (74.6) | 197 (92.1) | 116 (95.9) | | Missing | 14 (0.3) | 3 (0.3) | 0 (0.0) | 0 (0.0) |
| | Stage II, N (%) | N = 2,097 | N = 255 | 0.30 | N = 250 | N = 101 | 0.59 | | No | 240 (11.4) | 37 (14.5) | 20 (8.0) | 5 (5.0) | | Yes | 1,854 (88.4) | 218 (85.5) | 227 (90.8) | 95 (94.1) | | Missing | 3 (0.1) | 0 (0.0) | 3 (1.2) | 1 (1.0) |
| | Stage III, N (%) | N = 1,451 | N = 181 | 0.70 | N = 563 | N = 170 | 0.03 | | No | 247 (17.0) | 34 (18.8) | 64 (11.4) | 32 (18.8) | | Yes | 1,201 (82.8) | 147 (81.2) | 498 (88.5) | 137 (80.6) | | Missing | 3 (0.2) | 0 (0.0) | 1 (0.2) | 1 (0.6) |
| | Stage IV (A/B/C), N (%) | N = 214 | N = 36 | 0.84 | N = 1,993 | N = 561 | 0.005 | | No | 82 (38.3) | 14 (38.9) | 437 (21.9) | 160 (28.5) | | Yes | 130 (60.8) | 22 (61.1) | 1,552 (77.9) | 400 (71.3) | | Missing | 2 (0.9) | 0 (0.0) | 4 (0.2) | 1 (0.2) |
|
|
